# Study of CS-3150 in Patients With Essential Hypertension

> **NCT02890173** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 1001 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** CS-3150
- **DRUG:** Eplerenone

## Key facts

- **NCT ID:** NCT02890173
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-07-11
- **Final completion:** 2017-07-11
- **Target enrollment:** 1001 (ACTUAL)
- **Last updated:** 2018-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02890173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02890173, "Study of CS-3150 in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT02890173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*